08-05-2025
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q1 Sales Targets
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market's revenue expectations in Q1 CY2025, with sales flat year on year at $170.5 million. Its non-GAAP profit of $0.74 per share was 7.6% above analysts' consensus estimates.
Is now the time to buy Amphastar Pharmaceuticals? Find out in our full research report.
Amphastar Pharmaceuticals (AMPH) Q1 CY2025 Highlights:
Revenue: $170.5 million vs analyst estimates of $173.9 million (flat year on year, 2% miss)
Adjusted EPS: $0.74 vs analyst estimates of $0.69 (7.6% beat)
Operating Margin: 21.9%, down from 27.9% in the same quarter last year
Market Capitalization: $1.16 billion
Company Overview
Founded in 1996 and known for its expertise in complex drug formulations, Amphastar Pharmaceuticals (NASDAQ:AMPH) develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products.
Sales Growth
A company's long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Amphastar Pharmaceuticals grew its sales at an impressive 17.4% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis.
Amphastar Pharmaceuticals Quarterly Revenue
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Amphastar Pharmaceuticals's annualized revenue growth of 18.7% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated.
Amphastar Pharmaceuticals Year-On-Year Revenue Growth
This quarter, Amphastar Pharmaceuticals missed Wall Street's estimates and reported a rather uninspiring 0.8% year-on-year revenue decline, generating $170.5 million of revenue.
Looking ahead, sell-side analysts expect revenue to grow 1.2% over the next 12 months, a deceleration versus the last two years. This projection doesn't excite us and suggests its products and services will face some demand challenges. At least the company is tracking well in other measures of financial health.
Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend.
